Phreesia (PHR)
NYSE:PHR
PHR Stock Chart & Stats
$8.60
$0.87(3.22%)
At close: 4:00 PM EST
$8.60
$0.87(3.22%)
Day’s Range― - ―
52-Week Range$7.77 - $32.76
Previous CloseN/A
Volume173.69K
Average Volume (3M)2.40M
Market Cap
$520.13M
Enterprise Value$551.18M
Total Cash (Recent Filing)$73.83M
Total Debt (Recent Filing)$102.45M
Price to Earnings (P/E)347.9
Beta0.88
Next Earnings
May 28, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding60,763,065
10 Day Avg. Volume3,989,378
30 Day Avg. Volume2,401,956
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue1.15
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda18.71
Forecast
1Y Price Target
$15.40Price Target Upside79.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)0.32
Revenue Forecast (FY)$515.92M
Bulls Say, Bears Say
Bulls Say
Improving Profitability And Cash GenerationReported positive net income and record free cash flow alongside maintained adjusted operating profit guidance signal improving financial health and stronger cash generation.
Margin Expansion Via Artificial IntelligenceDeployment of artificial intelligence to automate manual tasks and reduce reliance on outsourced resources is poised to produce meaningful margin expansion and large cost savings, supporting profitability despite revenue pressure.
Revenue Diversification Through Payments And AcquisitionsExpansion of the payments business and the AccessOne acquisition diversify revenue away from pharmaceutical advertising and create new, higher-margin payment and financing opportunities.
Bears Say
Forecasting And Visibility RiskGreater sensitivity to the timing of pharmaceutical budgets has increased forecasting variability and reduced investor confidence in future revenue visibility.
Pharmaceutical Advertising PullbackReduced advertising spend from certain pharmaceutical clients, including lower priority on vaccine and public health content, has weakened Network Solutions revenue and pressured overall sales.
Reduced Revenue Outlook And Valuation PressureLowered revenue guidance and analyst price target cuts reflect a markedly slower revenue growth outlook that increases valuation compression risk.
Phreesia News
PHR FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest stock price was $7.77 and its highest was $32.76 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $520.13M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is May 28, 2026 which is in 42 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on Mar 30, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.065 by -$0.045.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Undervalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.01.
How many shares outstanding does Phreesia have?
Phreesia has 60,763,065 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.02 in its last earnings report, missing expectations of $0.065. Following the earnings report the stock price went down -26.556%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in PHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.40 (79.07% Upside)
$15.40 (79.07% Upside)
Blogger Sentiment
Bullish
PHR Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.42%
12-Months-Change
Fundamentals
Return on Equity
0.75%
Trailing 12-Months
Asset Growth
70.85%
Trailing 12-Months
Company Description
Phreesia
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
PHR Company Deck
PHR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights substantial progress on profitability and cash generation (first full-year positive GAAP net income, >$100M Adjusted EBITDA, >$50M free cash flow) and successful financing and acquisition integration (AccessOne performing as expected). Management preserved fiscal 2027 Adjusted EBITDA guidance and emphasized AI-driven efficiency opportunities. However, the company reduced fiscal 2027 revenue guidance due to shorter visibility and reduced commitments from certain pharmaceutical clients (notably vaccines and some public health spend), creating variability concentrated in the higher-margin Network Solutions segment. New initiatives (ProviderConnect) and AccessOne expansion offer upside but remain early-stage. Overall, the results show meaningful financial strength and execution, offset by near-term top-line uncertainty in a key segment.View all PHR earnings summariesPHR Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
PHR Stock 12 Month Forecast
Average Price Target
$15.40
▲(79.07% Upside)
Technical Analysis
Ownership Overview
6.04% Insiders
34.63% Mutual Funds
37.88% Other Institutional Investors
8.61% Public Companies and Individual Investors